Accu chek aviva glucometer

After 7–8 weeks on the experimental diets, mice underwent an intraperitoneal insulin challenge (1.5–2.0 IU of insulin per kg BW) following a 6-h water-only fast. Prior to insulin injection, baseline fasting glucose levels were measured from venous blood samples obtained via saphenous tail veins using an Accu-Chek^® Aviva glucometer (Roche Diagnostics, Laval, QC, Canada). Approximately 100 µL of blood was collected into heparin-coated capillary tubes (Cat# 20.1309.100, Sarstedt, Nümbrecht, Germany) for plasma analysis. Post-injection glucose levels were assessed at specific time points: 10, 20, 60, 90, and 120 min at TCP and 15, 30, 60, 90, and 120 min at DCM and CCBR. The rate constant for glucose disappearance (kITT) was calculated over the initial 15 min (DCM and CCBR) and 20 min (TCP) using the formula [17 (link)]:
Plasma samples were analyzed using commercially available ELISA kits to determine fasting insulin concentrations (Cat# 80-INSMSH-E01, Alpco Diagnostics, Salem, NH, USA). The homeostatic model assessment for insulin resistance (HOMA-IR), a proxy marker of insulin resistance based on fasting glucose and insulin levels, was calculated using the following equation [17 (link)]:

Blood glucose levels were measured in random-fed animals with a glucometer (Accu-Chek Aviva Glucometer, Roche Diagnostics). For the glucose tolerance test, mice were starved for 16 h in their home cages. After measurement of basal blood glucose levels, D-glucose (2 g/kg) was injected intraperitoneally, and blood glucose levels were measured at different time points during 2 h.

Mice were fasted for 16 hours with free access to water. Each mouse was then weighed and glucose measured from tail blood with Accu-Chek Aviva Glucometer (Roche). After obtaining baseline glucose measurements, each mouse was then injected intraperitoneally with a sterile solution of D-glucose at 1 mg/kg. Blood glucose measurements were then taken from tail bleeds for each animal at 15, 30, 60, 90 and 120 minutes.

The glucose tolerance test (GTT) was performed in mice that previously underwent a fasting period of 6 h. After the fasting period, the baseline glucose concentration in tail vein-derived blood was measured (0 min) using a handheld glucometer (Accu-Chek Aviva Glucometer, Roche, Basel, Switzerland) and blood glucose test strips (#06453970037; Roche, Basel, Switzerland). Afterwards, each mouse received an i.p. injection of glucose (2 g/kg body weight). Subsequently, the blood glucose concentration was measured 15, 30, 60, and 120 min after the glucose injection.

The insulin tolerance test (ITT) was carried out in ad libitum-fed mice. After measuring the baseline glucose concentration in tail vein-derived blood (0 min) with a handheld glucometer (Accu-Chek Aviva Glucometer, Roche, Basel, Switzerland), each mouse received an i.p. insulin administration (0.75 U/kg body weight; Actrapid; Novo Nordisk, Bagsværd, Denmark) and blood glucose concentration was subsequently monitored 15, 30, and 60 min after the insulin injection.

Mice were fasted for 6 hours with free access to water. Each mouse was then weighed and glucose measured from tail blood with Accu-Chek Aviva Glucometer (Roche). After obtaining baseline glucose measurements, each mouse was then injected intraperitoneally with a sterile solution of insulin at 0.75 U/kg. Blood glucose measurements were then taken from tail bleeds for each animal at 15, 30, 60, 90 and 120 minutes.